The 21% comes from a peer-reviewed article: Milbank Q. 2019 Sep;97(3):796-819. doi: 10.1111/1468-0009.12403. Epub 2019 Jul 14. Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008-2015
Audrey D Zhang, Jason L Schwartz, Joseph S Ross
The biggest turnaround from panel to FDA decision I can remember was a panel vote of 16:0:1 in favour of a product called Redectane, but FDA knocked it back based on insufficient number patient numbers.
I think you may need to apologise to Mr Richardson.
The 21% comes from a peer-reviewed article: Milbank Q. 2019...
-
- There are more pages in this discussion • 11,567 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |